DigiDOP: A framework for applying digital technology to the Differential Outcomes Procedure (DOP) for cognitive interventions in persons with neurocognitive disordersShow others and affiliations
2024 (English)In: Neuroscience and Biobehavioral Reviews, ISSN 0149-7634, E-ISSN 1873-7528, Vol. 165, article id 105838Article in journal (Refereed) Published
Abstract [en]
We present a framework –Digi-DOP- that includes a series of evidence-based recommendations to design and apply cognitive interventions for people with Neurocognitive Disorders (NCDs) using a relatively new approach, the Differential Outcomes Procedure (DOP). To do so, we critically review the substantial experimental research conducted with relevant clinical and non-clinical populations, and the theoretical underpinnings of this procedure. We further discuss how existing digital technologies that have been used for cognitive interventions could be applied to overcome some of the limitations of DOP-based interventions and further enhance DOP benefits. Specifically, we present three digital DOP developments that are currently being designed, investigated and/or tested. Finally, we discuss constraints, ethical and legal considerations that need to be taken into account to ensure that the use of technology in DOP-based interventions proposed here does not widen disparities and inequalities. We hope that this framework will inform and guide digital health leaders and developers, researchers and healthcare professionals to design and apply DOP-based interventions for people with NCDs.
Place, publisher, year, edition, pages
Elsevier Ltd , 2024. Vol. 165, article id 105838
Keywords [en]
cognition; digital health; digital technology; disorders of higher cerebral function; evidence based practice; health care personnel; human; review; therapy
National Category
Health Sciences
Identifiers
URN: urn:nbn:se:ri:diva-75020DOI: 10.1016/j.neubiorev.2024.105838Scopus ID: 2-s2.0-85201597505OAI: oai:DiVA.org:ri-75020DiVA, id: diva2:1895635
Note
This framework development has been funded by the Forte-JPND (Joint Programme for Neurodegenerative Disease Research), REF:JPNDWG2021-013.
2024-09-062024-09-062025-09-23Bibliographically approved